Delivery Order SPE2DR25D1053-SPE2DR26FT615
Award Date 11/5/25
Potential Completion Date 11/6/25
Potential Value $1.4K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $10,014.60 for 420 mg vials of Ontruzant on September 9, 2025, with completion scheduled for September 10, 2025. This firm fixed-price contract, issued with no set-aside designation, was competitively awarded by the Defense Logistics Agency's Medical Supply Chain to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $2,310.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ontruzant 150 mg vials, with an ultimate completion date of September 12, 2025. This non-set-aside delivery order was competitively awarded and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ontruzant 150 mg vials, with a ceiling value of $10,882.70. This firm fixed-price, non-competitive set-aside delivery order is scheduled for completion by August 5, 2025, and will be fulfilled from the contractor's corporate office location in Conshohocken, Pennsylvania. Ontruzant is a biosimilar therapeutic used in oncology treatment, reflecting the...
- The U.S. Department of Defense's Medical Supply Chain awarded a $1,312.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Ontruzant 150 mg vials, with final delivery required by September 15, 2025. This non-set-aside contract was competitively awarded to AmerisourceBergen's Corporate Office, headquartered in Conshohocken, Pennsylvania, where the pharmaceutical products will be sourced and delivered. The delivery order is a child contract...
- The Defense Logistics Agency awarded a $35.3K delivery order to AmerisourceBergen Drug Corp for the supply of Ontruzant 420 mg vials, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and designates AmerisourceBergen's Conshohocken, Pennsylvania facility as the place of performance. The delivery order is a child contract action issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Ontruzant 150 mg vials, a biosimilar oncology medication, with a ceiling value of $2,305.20. This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 23, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award utilized no set-aside designation, reflecting open competition for this medical...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $9,071.48 on June 2, 2025, for the supply of Ontruzant 150 mg vials under a firm fixed-price contract with the Defense Department's Medical Supply Chain. This is a non-set-aside award with an ultimate completion date of June 3, 2025, and performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. Ontruzant is a biosimilar monoclonal antibody used in oncology treatments, reflecting the federal...
- The Defense Logistics Agency (DLA) awarded a delivery order totaling $6,647.56 to AmerisourceBergen Drug Corp for the supply of Ontruzant 420 mg vials. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation, completed on August 4, 2025, with a final delivery date of August 5, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $5,748.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ontruzant 420 mg vials, with an ultimate completion date of August 22, 2025. The contract, issued on August 21, 2025, is a non-set-aside award reflecting open competition. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, serving as the prime contractor with no subcontractors identified. This...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for Ontruzant 150 mg vials valued at $10,937.50 on September 23, 2025. This firm fixed-price delivery order, which represents a child contract under a larger indefinite delivery vehicle, is scheduled for completion by September 24, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The award was competitively procured with no set-aside...